Review Article
Can the Neutrophil to Lymphocyte Ratio Be Used to Determine Gastric Cancer Treatment Outcomes? A Systematic Review and Meta-Analysis
Table 1
Characteristics of included studies.
| | Name | Year | Country | Patients
(female/male) | Age (range) | Treatment | Follow-up (month) | TMN (I/II/III/IV) | Tumor size | CEA | Tumor differentiation (well/poor) | Cutoff value | Number of elevated NLR |
| |
Mohri et al. [18] | 2014 | Japan | 123 (38/85) | Median: 66
(18–94) | Resection + chemotherapy | 9.3 | 0/0/0/123 | NA | NA | 45/78 | 3.1 | 118 | |
Jiang et al. [13] | 2014 | China | 377 (124/253) | Median: 64
(25–80) | Resection + chemotherapy | 42 | 37/99/241/0 | 140/237
(5 cm) | NA | 97/280 | 1.44 | 309 | |
Cho et al. [20] | 2014 | Korea | 268 (93/175) | Mean: 55.4 | Chemotherapy | 11.3 | 0/0/0/268 | NA | NA | 95/173 | 3 | 138 | |
Graziosi et al. [19] |
2015 | Italy | 156 (92/64) | Median: 74
(39–91) | Resection + chemotherapy | 23 | 42/29/62/23 | NA | NA | NA | 2.3 | 80 | |
Aurello et al. [21] | 2014 | Italy | 102 (40/62) | Median: 69 | Resection | 96 | 34/15/35/18 | NA | NA | NA | 5 | 28 | | El Aziz [22] | 2014 | Egypt | 70 (23/47) | Median: 53
(30–70) | Resection | NA | 0/0/49/21 | NA | NA | NA | 3 | 40 | |
Lee et al. [23] | 2013 | Korea | 174 (60/114) | Median: 55
(22–74) | Resection + Chemotherapy | 14.9 | 7/22/41/101 | NA | 58/118 | NA | 3 | 62 | |
Lee et al. [24] | 2013 | Korea | 220 (71/149) | Mean: 57
(23–89) | Resection | NA | 120/35/62/3 | 59/161 | 22/195 | NA | 2.15 | 56 | |
Jin et al. [25] | 2013 | China | 46 (10/36) | Median: 60
(37–77) | Resection + chemotherapy | NA | 0/0/40/6 | NA | NA | 15/31 | 2.5 | 20 | |
Dirican et al. [26] | 2013 | Turkey | 236 (74/162) | Median: 58
(30–86) | Resection + chemotherapy | NA | 6/20/105/105 | NA | NA | NA | 3.8 | 89 | |
Wang et al. [14] | 2012 | China | 324 (99/225) | NA | Resection + chemotherapy | 39.9 | 0/0/324/0 | 158/168
(5 cm) | NA | NA | 5 | 11 | |
Kunisaki et al. [27] | 2012 | Japan | 83 (26/57) | Mean: 67.7
(37–91) | Resection + chemotherapy | 14.5 | 0/0/22/61 | 10/73
(5 cm) | NA | 35/48 | 5 | 18 | |
Kim and Choi [28] | 2012 | Korea | 93 (36/57) | NA | Resection + chemotherapy | NA | 44/16/33/0 | 60/33
(5 cm) | NA | 44/49 | 1.8 | 36 | |
Jeong et al. [29] | 2012 | Korea | 104 (35/69) | Median: 52.5 (28–82) | Chemotherapy | 11.9 | 0/0/0/104 | NA | NA | 27/75 | 3 | 55 | |
Jung et al. [30] | 2011 | Korea | 293 (100/193) | Median: 63
(21–96) | Resection + chemotherapy | 27.2 | 0/0/143/150 | NA | NA | 73/220 | 2 | 155 | |
Ubukata et al. [31] | 2010 | Japan | 157 (51/106) | Mean: 65.27
(29–84) | Resection | NA | 45/30/39/43 | 42/115 | NA | 58/99 | 5 | 70 | |
Shimada et al. [32] | 2010 | Japan | 1028 (319/709) | Median: 65 (26–89) | Resection | 23 | 584/132/153/159 | NA | NA | 521/507 | 4 | 127 | |
Mohri et al. [33] | 2010 | Japan | 357 (112/245) | Median: 63.4
(32–87) | Resection | 68 | 232/57/68/0 | NA | NA | 198/159 | 2.2 | 130 | |
Yamanaka et al. [34] | 2007 | Japan | 1220 (351/869) | NA | Chemotherapy | 15.6 | 0/0/0/1220 | NA | NA | NA | 2.5 | 644 |
|
|
Tumor size ⩾ cutoff value/tumor size < cutoff value; CEA ⩾ cutoff value/CEA < cutoff value; the cutoff value of NLR; NLR: neutrophil to lymphocyte ratio; NA: not applicable; TNM: tumor node metastasis stage; CEA: carcinoembryonic antigen.
|
